264 related articles for article (PubMed ID: 8959080)
1. Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome.
Klinger B; Jensen LT; Silbergeld A; Laron Z
Clin Endocrinol (Oxf); 1996 Oct; 45(4):423-9. PubMed ID: 8959080
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism.
Laron Z; Klinger B; Jensen LT; Erster B
Clin Endocrinol (Oxf); 1991 Aug; 35(2):145-50. PubMed ID: 1934530
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent effects of recombinant human growth hormone on biochemical markers of bone and collagen metabolism in adult growth hormone deficiency.
Bollerslev J; Møller J; Thomas S; Djøseland O; Christiansen JS
Eur J Endocrinol; 1996 Dec; 135(6):666-71. PubMed ID: 9025710
[TBL] [Abstract][Full Text] [Related]
4. IGF-I treatment of adult patients with Laron syndrome: preliminary results.
Laron Z; Klinger B
Clin Endocrinol (Oxf); 1994 Nov; 41(5):631-8. PubMed ID: 7530175
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor axis, bone and collagen turnover in children with atopic dermatitis treated with topical glucocorticosteroids.
Wolthers OD; Heuck C; Ternowitz T; Heickendorff L; Nielsen HK; Frystyk J
Dermatology; 1996; 192(4):337-42. PubMed ID: 8864369
[TBL] [Abstract][Full Text] [Related]
6. [Effect of GH/IGF-I deficiency on bone and collagen turnover in children and adults with GH deficiency].
Sartorio A; Conti A; Monzani M; Ferrero S; Biella O; Casati G; Faglia G
Minerva Endocrinol; 1995 Jun; 20(2):135-40. PubMed ID: 8531895
[TBL] [Abstract][Full Text] [Related]
7. New markers of bone and collagen turnover in children and adults with growth hormone deficiency.
Sartorio A; Conti A; Monzani M
Postgrad Med J; 1993 Nov; 69(817):846-50. PubMed ID: 8290428
[TBL] [Abstract][Full Text] [Related]
8. Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia.
Crofton PM; Ahmed SF; Wade JC; Stephen R; Elmlinger MW; Ranke MB; Kelnar CJ; Wallace WH
J Clin Endocrinol Metab; 1998 Sep; 83(9):3121-9. PubMed ID: 9745414
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of carboxyterminal propeptide of type I procollagen and pyridinoline crosslinked telopeptide of type I collagen in normal children and children with growth hormone (GH) deficiency during GH therapy.
Kubo T; Tanaka H; Inoue M; Kanzaki S; Seino Y
Bone; 1995 Oct; 17(4):397-401. PubMed ID: 8573414
[TBL] [Abstract][Full Text] [Related]
10. Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers: a study on-the-field.
Sartorio A; Marazzi N; Agosti F; Faglia G; Corradini C; De Palo E; Cella S; Rigamonti A; Muller EE
J Endocrinol Invest; 2004 May; 27(5):410-5. PubMed ID: 15279071
[TBL] [Abstract][Full Text] [Related]
11. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG).
Abildgaard N; Bentzen SM; Nielsen JL; Heickendorff L
Br J Haematol; 1997 Jan; 96(1):103-10. PubMed ID: 9012695
[TBL] [Abstract][Full Text] [Related]
12. Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy.
Kjeldsen J; Schaffalitzky de Muckadell OB; Junker P
Gut; 1995 Dec; 37(6):805-10. PubMed ID: 8537052
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment.
Terzolo M; Piovesan A; Osella G; Pia A; Reimondo G; Pozzi C; Raucci C; Torta M; Paccotti P; Angeli A
Calcif Tissue Int; 1993 Mar; 52(3):188-91. PubMed ID: 8481830
[TBL] [Abstract][Full Text] [Related]
14. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
Akimoto S; Akakura K; Shimazaki J
Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
[TBL] [Abstract][Full Text] [Related]
15. Effect of growth hormone (GH) replacement on plasma carboxy-terminal propeptide of type I procollagen (PICP) and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) levels in GH-deficient adult patients.
Murakami Y; Sugitani M; Koshimura K; Sohmiya M; Kato Y
Endocr J; 1998 Apr; 45 Suppl():S121-4. PubMed ID: 9790245
[No Abstract] [Full Text] [Related]
16. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
Kotzmann H; Riedl M; Pietschmann P; Schmidt A; Schuster E; Kreuzer S; Kainberger F; Frisch H; Geyer G; Hörl WH; Mayer G; Luger A
J Nephrol; 2004; 17(1):87-94. PubMed ID: 15151263
[TBL] [Abstract][Full Text] [Related]
17. IGF binding protein 3 in patients with Laron type dwarfism: effect of exogenous rIGF-I.
Laron Z; Klinger B; Blum WF; Silbergeld A; Ranke MB
Clin Endocrinol (Oxf); 1992 Mar; 36(3):301-4. PubMed ID: 1373347
[TBL] [Abstract][Full Text] [Related]
18. Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major.
Sartorio A; Conte G; Conti A; Masala A; Alagna S; Rovasio P; Faglia G
J Endocrinol Invest; 2000 Jun; 23(6):356-61. PubMed ID: 10908162
[TBL] [Abstract][Full Text] [Related]
19. Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency.
Magnusson P; Degerblad M; Sääf M; Larsson L; Thorén M
J Bone Miner Res; 1997 Feb; 12(2):210-20. PubMed ID: 9041052
[TBL] [Abstract][Full Text] [Related]
20. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults.
Välimäki MJ; Salmela PI; Salmi J; Viikari J; Kataja M; Turunen H; Soppi E
Eur J Endocrinol; 1999 Jun; 140(6):545-54. PubMed ID: 10377504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
